Ronen Bezalel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a preclinical biopharmaceutical company, and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, announce their entry into a definitive merger agreement pursuant to which the shareholders of Chemomab wou

United kingdomAnchiano adssRonen bezalelStan polovetsNeil cohenPeter thielShachar hadarGoldfarb seligmanStephen squintoWadi morOppenheimer co incChemomab therapeutics ltdExchange commissionCompany annual report on formGreenberg traurigAnchiano therapeutics ltd